Subscribe
shutterstock_2026137224_flowersandtraveling
Flowersandtraveling / Shutterstock.com
28 June 2022Big PharmaMuireann Bolger

Pfizer sued over COVID-19 antiviral drug

Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets), after Enanta Pharmaceuticals filed a complaint citing patent infringement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pfizer commits to offer drugs not-for-profit to 45 low-income countries
31 May 2022   Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
Pharma company hit with racial discrimination lawsuit
20 September 2022   Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Pfizer commits to offer drugs not-for-profit to 45 low-income countries
31 May 2022   Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
Pharma company hit with racial discrimination lawsuit
20 September 2022   Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.

More on this story

Big Pharma
Pfizer commits to offer drugs not-for-profit to 45 low-income countries
31 May 2022   Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
Americas
Pfizer bolsters haematology expertise with $5.4bn deal
9 August 2022   Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.
Big Pharma
Pharma company hit with racial discrimination lawsuit
20 September 2022   Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York